Neurostimulation Devices Market size to exceed USD 19bn by 2025

Neurostimulation Devices Market size is set to exceed USD 19 billion by 2025; according to a new research report by Global Market Insights, Inc.
 

Technological advancements coupled with growing adoption of innovative neurostimulators will accelerate the neuro stimulation devices market demand. Focus of industry players on introducing technologically advanced and cost-effective devices to improve patient convenience will favor business growth. Rising demand for detection of different illness including gastroparesis, Parkinson’s disease, dystonia and depression among others will boost the demand for neuromodulation devices.

 

Request Sample Buy NowInquiry Before Buying

 

Furthermore, increasing preference towards minimally invasive surgical techniques in developed economies should render positive impact on neurostimulator devices market growth. Advent in technology has led to reduced treatment costs, less pain, and faster recovery time for patients undergoing minimally invasive treatments. Additionally, other advantages including smaller incision length, minimum discomfort and less blood loss during the surgery make it a preferable treatment option. Thus, developments in neurostimulation techniques will upsurge the market growth. However, complications associated with neuromodulation may restrict neurostimulation devices business demand over the coming years.
 

U.S. Neurostimulation Devices Market, By Product, 2018 & 2025 (USD Million)
Neurostimulation Devices Market

Get more details on this report - Request Free Sample PDF
 

Spinal cord stimulators segment was valued around 3.5 billion in 2018 and will witness lucrative growth during the forecast period. Rising adoption of spinal cord stimulators and several efforts undertaken by business players to develop progressive products should propel implantable neurostimulation devices market growth. For instance, the rechargeable spinal cord stimulator for chronic pain reduces the requirement for repetition of surgical procedures thereby, improving patient’s quality of life. Abovementioned factor will thus prove beneficial for segment growth during the forthcoming years.
 

Pain management segment accounted for over 60% revenue share in 2018 and will show substantial CAGR by 2025. Increasing incidence of chronic pain along with approval and launch of novel devices, that aid in reducing chronic pain will boost segment growth. Moreover, awareness regarding availability of different pain management devices will further augment neurostimulation devices market growth.
 

Browse key industry insights spread across 130 pages with 124 market data tables & 8 figures & charts from the report, “Neurostimulation Devices Market Size By Product (Deep Brain, Gastric Electric, Spinal Cord, Sacral Nerve, Vagus Nerve), By Application (Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson’s Disease), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, China, Japan, India, Brazil, Mexico, South Africa, Saudi Arabia), Application Potential, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/neurostimulation-devices-market-report
 

North America neurostimulation devices market is poised to show lucrative CAGR of more than 13.5% over the forecast period. Timely introduction of novel devices along with rapidly rising incidence of neurological diseases in the region is the key factor driving demand for these devices. Moreover, growing demand for minimally invasive treatments will favor North American market growth.
 

Some of the notable industry players functioning in neurostimulation devices market include Boston Scientific, Medtronic, Bayer, IntraPace, Neuronetics, Nevro, ImThera Medical, Uroplasty and St. Jude Medical. Several initiatives undertaken by business players including collaborations and partnerships will prove beneficial for overall industry growth. For instance, in December 2017, Boston Scientific Corporation’s Vercise Deep Brain Stimulation (DBS) System received U.S. FDA approval for treating symptoms of Parkinson's disease (PD). This enabled company to strengthen its existing product portfolio. Furthermore, in September 2017, Medtronic launched Intellis platform for managing certain types of chronic intractable pain in the U.S. This platform can record and track patient activity enabling physicians to address the cause. The launch enabled company to gain more revenue share.
 

Inquiry Before BuyingRequest Sample
 

Neurostimulation devices market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2014 to 2025, for the following segments:
 

By Product, 2014-2025 (USD Million)

  • Deep brain stimulator
  • Gastric electric stimulator
  • Spinal cord stimulator
  • Sacral nerve stimulator
  • Vagus nerve stimulator

By Application, 2014-2025 (USD Million)

  • Pain Management
  • Epilepsy
  • Essential Tremor
  • Urinary and Fecal Incontinence
  • Depression
  • Dystonia
  • Gastroparesis
  • Parkinson's Disease
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
    • Mexico
  • Middle East Asia & Africa
    • South Africa
    • Saudi Arabia

 

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X